SPOTLIGHT: Biotechs, Columbia settle patent fight

A big patent battle between Genzyme and Biogen Idec on one side and Columbia University on the other has been settled. Terms of the settlement were not disclosed. Legal experts had been closely focused on the case, which centered on access to publicly funded research and the royalties drug companies pay for that technology. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.